Proteomics analysis of plasma from middle-aged adults identifies protein markers of dementia risk in later life
Open accessThe DOI matches its Crossref record; 109 of the 109 references it cites were found in a registry or an index.
Abstract
A diverse set of biological processes have been implicated in the pathophysiology of Alzheimer’s disease (AD) and related dementias. However, there is limited understanding of the peripheral biological mechanisms relevant in the earliest phases of the disease. Here, we used a large-scale proteomics platform to examine the association of 4877 plasma proteins with 25-year dementia risk in 10,981 middle-aged adults. We found 32 dementia-associated plasma proteins that were involved in proteostasis, immunity, synaptic function, and extracellular matrix organization. We then replicated the association between 15 of these proteins and clinically relevant neurocognitive outcomes in two independent cohorts. We demonstrated that 12 of these 32 dementia-associated proteins were associated with cerebrospinal fluid (CSF) biomarkers of AD , neurodegeneration, or neuroinflammation. We found that eight of these candidate protein markers were abnormally expressed in human postmortem brain tissue from patients with AD, although some of the proteins that were most strongly associated with dementia risk, such as GDF15, were not detected in these brain tissue samples. Using network analyses, we found a protein signature for dementia risk that was characterized by dysregulation of specific immune and proteostasis/autophagy pathways in adults in midlife ~20 years before dementia onset, as well as abnormal coagulation and complement signaling ~10 years before dementia onset. Bidirectional two-sample Mendelian randomization genetically validated nine of our candidate proteins as markers of AD in midlife and inferred causality of SERPINA3 in AD pathogenesis. Last, we prioritized a set of candidate markers for AD and dementia risk prediction in midlife.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
American Psychiatric Association (2013) · doi:10.1176/appi.books.9780890425596 · Cited by 116,369
Gene Ontology: tool for the unification of biology
Ashburner, M., Ball, C. A., Blake, J. A., Botstein, D., Butler, H., Cherry, J. M., Davis, A. P., Dolinski, K., Dwight, S. S., Eppig, J. T., et al. (2000) · Nature Genetics · doi:10.1038/75556 · Cited by 43,206
PLINK: a tool set for whole-genome association and population-based linkage analyses.
Purcell, S., Neale, B., Todd-Brown, K., Thomas, L., Ferreira, M. A. R., Bender, D., Maller, J., Sklar, P., de Bakker, P. I. W., Daly, M. J., et al. (2007) · The American Journal of Human Genetics · doi:10.1086/519795 · Cited by 34,089
WGCNA: an R package for weighted correlation network analysis
Langfelder, P., & Horvath, S. (2008) · BMC Bioinformatics · doi:10.1186/1471-2105-9-559 · Cited by 27,252
Kok, J. S., Berg, I. J., & Scherder, E. J. A. (2013) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000353441 · Cited by 20,589
A simple salting out procedure for extracting DNA from human nucleated cells
Miller, S. A., Dykes, D. D., & Polesky, H. F. (1988) · Nucleic Acids Research · doi:10.1093/nar/16.3.1215 · Cited by 20,330
Tissue-based map of the human proteome
Uhlén, M., Fagerberg, L., Hallström, B. M., Lindskog, C., Oksvold, P., Mardinoglu, A., Sivertsson, Å., Kampf, C., Sjöstedt, E., Asplund, A., et al. (2015) · Science · doi:10.1126/science.1260419 · Cited by 15,286
NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease
Jack, C. R., Bennett, D. A., Blennow, K., Carrillo, M. C., Dunn, B., Haeberlein, S. B., Holtzman, D. M., Jagust, W., Jessen, F., Karlawish, J., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.02.018 · Cited by 10,537
The Clinical Dementia Rating (CDR): Current version and scoring rules
Morris, J. C. (1993) · Neurology · doi:10.1212/wnl.43.11.2412-a · Cited by 9,882
Bowden, J., Davey Smith, G., & Burgess, S. (2015) · International Journal of Epidemiology · doi:10.1093/ije/dyv080 · Cited by 9,816
Research works printed but not linked: 2
- Lezak M, Malec J, Manual for the Mayo-Portland Adaptability Inventory (MPAI-4) for adults, children and adolescents (2008). [Google Scholar]
- Heim A, AH 4 Group Test of General Intelligence (NFER-Nelson Publishing Company, 1970). [Google Scholar]
Cited by
Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission
Livingston, G., Huntley, J., Liu, K. Y., Costafreda, S. G., Selbæk, G., Alladi, S., Ames, D., Banerjee, S., Burns, A., Brayne, C., et al. (2024) · The Lancet · doi:10.1016/s0140-6736(24)01296-0 · Cited by 3,860
Plasma proteomic profiles predict future dementia in healthy adults
Guo, Y., You, J., Zhang, Y., Liu, W.-S., Huang, Y.-Y., Zhang, Y.-R., Zhang, W., Dong, Q., Feng, J.-F., Cheng, W., et al. (2024) · Nature Aging · doi:10.1038/s43587-023-00565-0 · Cited by 293
“No statistical methods were used to predetermine sample size, but our sample size is similar to or even higher than those reported in previous publications 18,53 .”
MethodResultDohm-Hansen, S., English, J. A., Lavelle, A., Fitzsimons, C. P., Lucassen, P. J., & Nolan, Y. M. (2024) · Trends in Neurosciences · doi:10.1016/j.tins.2024.02.001 · Cited by 122
“…analysis of samples taken at middle age revealed synaptic, proteostatic, and immune-and microglia-related proteins that were associated with incident dementia 25 years later, neuroimaging-derived phenotypes 5 years later (e.g., white matter hyperintensities), and CSF in fl ammatory load [33,34].”
BackgroundInfluentialChadarevian, J. P., Hasselmann, J., Lahian, A., Capocchi, J. K., Escobar, A., Lim, T. E., Le, L., Tu, C., Nguyen, J., Kiani Shabestari, S., et al. (2024) · Neuron · doi:10.1016/j.neuron.2024.05.023 · Cited by 83
Plasma proteomics identify biomarkers and undulating changes of brain aging
Liu, W., You, J., Chen, S.-D., Zhang, Y., Feng, J., Xu, Y., Yu, J., & Cheng, W. (2024) · Nature Aging · doi:10.1038/s43587-024-00753-6 · Cited by 102
“Plasma GFAP was significantly associated with risk of incident ACD (HR = 2.066, P = 2.23 × 10 −76 ), AD (HR = 2.393, P = 1.59 × 10 −71 ) and VD (HR = 2.281, P = 4.66 × 10 −29 ).”
InfluentialShen, C., Zhang, R., Yu, J., Sahakian, B. J., Cheng, W., & Feng, J. (2025) · Nature Human Behaviour · doi:10.1038/s41562-024-02078-1 · Cited by 94
“Finally, we aggregated information in the modules using the first PC. Consistent with prior network-based proteomic analyses 95 , we set the minimum module size to 20, applied a Spearman filter method with a soft power of β = 2 and an ‘unsigned’ network approach in clustering.”
Gan, Y., Ma, L., Zhang, Y., You, J., Guo, Y. X., He, Y., Wang, L., He, X.-Y., Li, Y., Dong, Q., et al. (2025) · Nature Aging · doi:10.1038/s43587-025-00818-0 · Cited by 79
“The relationship between ITGAM and PD appeared contradictory in our Cox-regression and MR analyses, similar to previous studies 49,50 .”
Adapting health, economic and social policies to address population aging in China
Fang, E. F., Fang, Y., Chen, G., Wang, H., Zhang, J., Wu, C., Liao, J., Xie, C., Liu, X., Wang, K., et al. (2025) · Nature Aging · doi:10.1038/s43587-025-00999-8 · Cited by 79
“During the past years, many circulating biomarkers of aging have been studied, with considerable attention given to biomarkers such as growth differentiation factor 15 (GDF15) 72 , chitotriosidase (CHIT1) 73 , the C–”
Dammer, E. B., Shantaraman, A., Ping, L., Duong, D. M., Gerasimov, E. S., Ravindran, S. P., Gudmundsdottir, V., Frick, E. A., Gomez, G. T., Walker, K. A., et al. (2024) · Science Translational Medicine · doi:10.1126/scitranslmed.adn3504 · Cited by 54
“…factor 15 (GDF15) that have no known expression in the brain have been associated with all-cause dementia up to 25 years later ( 44 ), highlighting the possibility that the APOE ε 4–associated modules observed in this study may simply reflect a systemic process observable in…”
BackgroundSelf-citationKivimäki, M., Frank, P., Pentti, J., Jokela, M. M., Nyberg, S. T., Blake, A., Lindbohm, J. V., Oh, H. S., Singh‐Manoux, A., Wyss‐Coray, T., et al. (2025) · The Lancet Digital Health · doi:10.1016/j.landig.2025.01.006 · Cited by 71
Self-citationA Survey on Computational Methods in Drug Discovery for Neurodegenerative Diseases
Vicidomini, C., Fontanella, F., D’Alessandro, T., & Roviello, G. N. (2024) · Biomolecules · doi:10.3390/biom14101330 · Cited by 50
“A large-scale proteomics study examined 4877 plasma proteins in over 10,000 middle-aged individuals and identified 32 proteins associated with a 25-year risk of developing dementia [17].”
BackgroundCentral role of the ER proteostasis network in healthy aging
Hetz, C. A., & Dillin, A. G. (2024) · Trends in Cell Biology · doi:10.1016/j.tcb.2024.10.003 · Cited by 42
Chen, L., Luo, S., Liu, T., Shuai, Z., Song, Y., Yang, Q., Wang, Y., Huang, H., & Luo, Y. (2025) · Journal of Neuroinflammation · doi:10.1186/s12974-025-03369-8 · Cited by 39
“Moreover, elevated serum GDF15 levels are closely linked with a greater likelihood of developing dementia [27, 28].”
Heparin-enriched plasma proteome is significantly altered in Alzheimer’s disease
Guo, Q., Ping, L., Dammer, E. B., Duong, D. M., Yin, L., Xu, K., Shantaraman, A., Fox, E. J., Golde, T. E., Johnson, E. C. B., et al. (2024) · Molecular Neurodegeneration · doi:10.1186/s13024-024-00757-1 · Cited by 40
“Notably, proteins of interest in M26 included SERPINA3, which was recently identified through a large-scale analysis of the plasma proteome using Mendelian randomization as potentially causal in AD pathogenesis [80].”
BackgroundGulej, R., Patai, R., Ungvari, A., Kállai, A., Tarantini, S., Yabluchanskiy, A., Huffman, D. M., Conboy, M. J., Conboy, I. M., Kivimäki, M., et al. (2025) · GeroScience · doi:10.1007/s11357-025-01657-y · Cited by 32
Wang, S., Rao, Z., Cao, R., Blaes, A. H., Coresh, J., Deo, R., Dubin, R. F., Joshu, C. E., Lehallier, B., Lutsey, P. L., et al. (2024) · PLoS Medicine · doi:10.1371/journal.pmed.1004464 · Cited by 28
Self-citationMendelian randomization identifies proteins involved in neurodegenerative diseases
Belbasis, L., Morris, S., van Duijn, C. M., Bennett, D., & Walters, R. G. (2025) · Brain · doi:10.1093/brain/awaf018 · Cited by 36
“151-153 We observed that there is no agreement between the proteins in our study and the proteins identified from the observational analyses.”
Li, C., Stebbins, R. C., Noppert, G. A., Carney, C. X., Liu, C., Sapp, A. R. M., Watson, E. J., & Aiello, A. E. (2023) · Molecular Psychiatry · doi:10.1038/s41380-023-02355-x · Cited by 25
Associations of plasma proteomics and age-related outcomes with brain age in a diverse cohort
Casanova, R., Walker, K. A., Justice, J. N., Anderson, A., Duggan, M. R., Cordon, J., Barnard, R., Lu, L., Hsu, F., Sedaghat, S., et al. (2024) · GeroScience · doi:10.1007/s11357-024-01112-4 · Cited by 25
“Other groups have reported proteomic signatures predictive of different phenotypes such as frailty [14–17], mobility disability [18], and incident dementia [19, 20].”
Self-citationZhang, Y., Guo, Y. X., He, Y., You, J., Zhang, Y., Wang, L., Chen, S., He, X., Yang, L., Huang, Y., et al. (2024) · Molecular Psychiatry · doi:10.1038/s41380-024-02840-x · Cited by 29
Duggan, M. R., Yang, Z., Cui, Y., Dark, H. E., Wen, J., Erus, G., Hohman, T. J., Chen, J., Lewis, A., Moghekar, A., et al. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.14142 · Cited by 21
Self-citationWalker, K. A., An, Y., Moghekar, A., Moaddel, R., Duggan, M. R., Peng, Z., Tian, Q., Pilling, L. C., Drouin, S. M., Espeland, M. A., et al. (2024) · Molecular Neurodegeneration · doi:10.1186/s13024-024-00772-2 · Cited by 22
“In addition to demonstrating that widely recognized ADRD biomarkers, such as CHI3L1 (YKL-40) [42], NfL [43], and GDF15 [44] are similarly associated with future cognitive impairment among APOEε 4 carriers and APOEε 3 homozygotes, we identified a set of 8 proteins to be uniquely predictive of future…”
BackgroundSelf-citationIsik, F. I., Thomson, S., Cueto, J. F., Spathos, J., Breit, S. N., Tsai, V. W.-W., Brown, D. A., & Finney, C. A. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1514518 · Cited by 30
Plasma proteomics for cognitive decline and dementia—A Southeast Asian cohort study
Sim, M. A., Doecke, J. D., Liew, O. W., Wong, L. L., Tan, E. S. J., Chan, S. P., Chong, J. R., Cai, Y., Hilal, S., Venketasubramanian, N., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.14577 · Cited by 28
Cerebrospinal fluid proteomics identification of biomarkers for amyloid and tau PET stages
Wang, Z., Chen, Y., Gong, K., Zhao, B., Ning, Y., Chen, M., Li, Y., Ali, M., Timsina, J., Liu, M., et al. (2025) · Cell Reports Medicine · doi:10.1016/j.xcrm.2025.102031 · Cited by 31
da Purificação, A. D., Debbas, V., Tanaka, L. Y., Gabriel, G. V. D. M., Wosniak, J., Bessa, T. C. D., Garcia-Rosa, S., Laurindo, F. R. M., & Oliveira, P. (2023) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2023.130502 · Cited by 18
Divergent biological pathways linking short and long sleep durations to mental and physical health
Li, Y., Gong, W., Sahakian, B. J., Huang, S., Zhang, W., Zhao, Y., Ma, L., Naismith, S. L., Yu, J., Jia, T., et al. (2025) · Nature Mental Health · doi:10.1038/s44220-025-00395-6 · Cited by 24
“https://doi.org/10.1038/s44220-025-00395-6 protein GDF15, which has been identified as a robust prognostic protein for multiple diseases, such as heart disease and dementia, in a previous study 52 .”
InfluentialPlasma proteomic associations with Alzheimer’s disease endophenotypes
Afshar, S., Dammer, E. B., Bian, S., Bennett, D. A., Mohs, R. C., Beauregard, D., Dwyer, J. R., Hales, C. M., Goldstein, F. C., Parker, M. W., et al. (2025) · Nature Aging · doi:10.1038/s43587-025-00965-4 · Cited by 31
“…significant level (all converters) with proteins associated with risk of cognitive decline in the Atherosclerosis Risk in Communities (ARIC) cohort 18,19 , and we identified CPLX1, ephrin type-A receptor 2 (EPHA2) and collagen alpha-1(X) chain (COL10A1) that were commonly associated with…”
A GDF-15–GFRAL axis controls autoimmune T cell responses during neuroinflammation
Sonner, J. K., Kahn, A., Binkle-Ladisch, L., Engler, J. B., Haack, B., Zeiler, C., Unger, L., Bauer, S., Fischbach, F., Almanzar, G., et al. (2026) · Nature Immunology · doi:10.1038/s41590-025-02406-1 · Cited by 17
“In accordance with previous reports using peripheral GDF-15 as a biomarker for neurodegenerative diseases 33,34 , plasma GDF-15 levels were elevated in the chronic phase of the disease (29 days after EAE induction; Extended Data Fig.”
Krix, S., Wilczynski, E., Falgàs, N., Sánchez‐Valle, R., Yoles, E., Nevo, U., Baruch, K., & Fröhlich, H. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1343900 · Cited by 23
Genome‐wide meta‐analysis identifies ancestry‐specific loci for Alzheimer's disease
Ge, Y., Chen, S., Wu, B., Zhang, Y.-R., Wang, J., He, X., Liu, W., Chen, Y., Ou, Y., Shen, X., et al. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.14121 · Cited by 16
Plasma proteomics for risk prediction of Alzheimer's disease in the general population
Yang, S., Ye, Z., He, P., Zhang, Y., Liu, M., Zhou, C., Zhang, Y., Gan, X., Huang, Y., Xiang, H., et al. (2024) · Aging Cell · doi:10.1111/acel.14330 · Cited by 19
“(Walker et al., 2021, 2023 ; You et al., 2023 ) Given that all-cause dementia is a composite outcome, different subtypes of dementia, including AD, vascular dementia, frontotemporal dementia, etc., may have different characteristic proteins.”
Macura, I. J., Živanović, A., Perović, M., Ciric, J., Major, T., Kanazir, S., & Ivković, S. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241814092 · Cited by 18
Hou, X., Qiu, Y., Li, H., Yan, Y., Zhao, D., Ji, S., Ni, J., Zhang, J., Liu, K., Qing, H., et al. (2025) · Alzheimer s Research & Therapy · doi:10.1186/s13195-025-01789-5 · Cited by 17
“Several studies have identified potential biochemical biomarkers in blood [30, 31] and CSF [12, 32], however, ML methods have seen limited application in the discovery of new biomarkers.”
Plasma proteomic analysis identifies proteins and pathways related to Alzheimer's risk
Huang, Y.-N., Liu, S., Park, T., Chaudhuri, S., Kuchenbecker, L. A., Carrasquillo, M. M., Ertekin‐Taner, N., Bice, P. J., Zetterberg, H., Blennow, K., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70579 · Cited by 20
Fluid-Based Protein Biomarkers in Traumatic Brain Injury: The View from the Bedside
Agoston, D. V., & Helmy, A. E. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242216267 · Cited by 17
“The various forms and phases of the inflammatory process can be identified with a serial analysis of blood or CSF [77–79].”
BackgroundAmontree, M., Nelson, M., Stefansson, L., Pak, D. T. S., Maguire‐Zeiss, K. A., Turner, R. S., & Conant, K. E. (2024) · Journal of Neurochemistry · doi:10.1111/jnc.16031 · Cited by 16
“…resveratrol sample size, most notably for APOE4 homozygous individuals, is a limitation of this study, overall results are consistent with a variety of recent studies that have highlighted ECM effector changes with AD and APOE4 (Labib et al., 2022 ; Tcw et al., 2022 ; Walker et al., 2023 ).”
Sun, D., Wang, R., Du, Q., Chen, H., Shi, Z., Zhang, Y., Zhang, N., Wang, X., & Zhou, H. (2024) · Journal of Affective Disorders · doi:10.1016/j.jad.2024.07.135 · Cited by 12
Pine, A. B., Butt, A., Andréoli, L., Knight, J. S., Gerosa, M., Cecchi, I., Branch, D. W., Lopez-Pedrera, R., Belmont, M. H., Kello, N., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1676578 · Cited by 12
“We utilized gene annotation and analysis resources for functional enrichment analysis has been previously done (15, 16, 18).”
A supervised Bayesian factor model for the identification of multi-omics signatures
Gygi, J. P., Konstorum, A., Pawar, S., Aron, E., Kleinstein, S. H., & Guan, L. (2024) · Bioinformatics · doi:10.1093/bioinformatics/btae202 · Cited by 13
“Walker et al. (2023) identified potential protein biomarkers of dementia via Cox proportional hazards regression modeling.”
Mielke, M. M., Fielding, R. A., Atkinson, E. J., Aversa, Z., Schafer, M. J., Cummings, S. R., Pahor, M., Leeuwenburgh, C., & LeBrasseur, N. K. (2025) · The journal of nutrition health & aging · doi:10.1016/j.jnha.2025.100529 · Cited by 15
An interpretable deep learning framework identifies proteomic drivers of Alzheimer’s disease
Panizza, E., & Cerione, R. A. (2024) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2024.1379984 · Cited by 11
“Recent studies have shown that plasma protein expression levels change during aging and identi fi ed protein signatures that predict health and disease in older age (Oh et al., 2023; Walker et al., 2023).”
BackgroundSeddon, A. R., MacArthur, C. P., Hampton, M. B., & Stevens, A. J. (2024) · Redox Report · doi:10.1080/13510002.2024.2428152 · Cited by 12
Duggan, M. R., Yang, S., Gómez, G., Cui, Y., Capuano, A. W., Chen, J., Yang, Z., Wen, J., Erus, G., Drouin, S. M., et al. (2025) · Science Advances · doi:10.1126/sciadv.adt7176 · Cited by 13
“The use of high-throughput proteomic platforms can enable these insights by identifying reliable, scalable predictors and determinants of neurode-generation ( 17 ).”
Self-citationGuo, Q. J., Ping, L., Dammer, E. B., Duong, D. M., Yin, L., Xu, K., Shantaraman, A., Fox, E. J., Johnson, E. C. B., Roberts, B. R., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.11.06.565824 · Cited by 11
Unraveling the role of proteins in dementia: insights from two UK cohorts with causal evidence
Gong, J., Williams, D. M., Scholes, S., Assaad, S., Bu, F., Hayat, S. A., Zaninotto, P., & Steptoe, A. (2025) · Brain Communications · doi:10.1093/braincomms/fcaf097 · Cited by 19
“10 Interestingly, our sensitivity analysis, which excluded APOE ϵ 4 carriers observed an attenuation in association between RPS6KB1 and dementia after considering multiple testing.”
InfluentialDammer, E. B., Shantaraman, A., Ping, L., Duong, D. M., Gerasimov, E. S., Ravindran, S. P., Guðmundsdóttir, V., Frick, E. A., Gómez, G., Walker, K. A., et al. (2023) · medRxiv · doi:10.1101/2023.10.29.23297651 · Cited by 10
Self-citationRehman, H., Ang, T. F. A., Tao, Q., Au, R., Farrer, L. A., Qiu, W. Q., Zhang, X., & Initiative, A. D. N. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70066 · Cited by 9
Arif, M., Lehoczki, A., Haskó, G., Lohoff, F. W., Ungvari, Z. I., & Pacher, P. (2025) · GeroScience · doi:10.1007/s11357-025-01672-z · Cited by 14
“…II study, the Atherosclerosis Risk in Communities (ARIC) study, and the UK Biobank, have further substantiated the link between increased GDF15 levels and an elevated risk of developing dementia, highlighting its potential as a biomarker for neurodegenerative disease risk and progression [54–58].”
Gong, J., & Zaninotto, P. (2025) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph22060815 · Cited by 10
Colinet, M., Chiver, I., Bonafina, A., Masset, G., Almansa, D., Valentin, E. D., Twizere, J., Nguyen, L., & Espuny-Camacho, I. (2025) · Stem Cells · doi:10.1093/stmcls/sxaf010 · Cited by 10
“Strikingly, a known pro-inflammatory protein expressed in astrocytes, SERPINA3, which has been detected in plasma of middle-aged adults with high risk for dementia, 75 was also upregulated in our infected cortical organoids.”
Caro, I., Western, D., Namba, S., Sun, N., Kawaguchi, S., He, Y., Fujita, M., Roshchupkin, G. V., D’Aoust, T., Duperron, M., et al. (2025) · Nature Aging · doi:10.1038/s43587-025-01006-w · Cited by 25
“9) 35 .”
Self-citationGong, J., Williams, D. M., Scholes, S., Assaad, S., Bu, F., Hayat, S. A., Zaninotto, P., & Steptoe, A. (2024) · medRxiv · doi:10.1101/2024.06.04.24308415 · Cited by 8
Rehman, H., Initiative, F. T. A. D. N., Ang, T. F. A., Tao, Q., Espenilla, A. L., Au, R., Farrer, L. A., Zhang, X., & Qiu, W. Q. (2024) · Journal of Alzheimer's Disease · doi:10.3233/jad-230837 · Cited by 7
“In this study, 32 dementia-associated plasma proteins were revealed to be involved in proteostasis, immunology, synaptic function, and extracellular matrix architecture [40].”
Yang, J., Bernard, L., Chen, J., Sullivan, V. K., Deal, J. A., Kim, H., Yu, B., Steffen, L. M., & Rebholz, C. M. (2025) · Journal of Nutrition · doi:10.1016/j.tjnut.2025.03.015 · Cited by 10
Self-citationProteomic signature of dementia risk in type 2 diabetes
Wang, Z., Ning, Y., Gao, P., Xu, L., Cao, S., Li, Y., & Jia, J. (2025) · Journal of Advanced Research · doi:10.1016/j.jare.2025.08.012 · Cited by 10
Kloske, C. M., Mahinrad, S., Barnum, C. J., Batista, A. F., Bradshaw, E. M., Butts, B., Carrillo, M. C., Chakrabarty, P., Chen, X., Craft, S., et al. (2024) · Alzheimer s & Dementia · doi:10.1002/alz.14291 · Cited by 7
“115,116 Toascertainwhichbloodproteinsmay increase AD risk, researchers can now make use of protein quantitative trait loci (pQTLs) recently made available as a result of the broad implementation of high-throughput proteomic platforms and genetic analysis on a population level.”
Self-citationHomann, J., Korologou‐Linden, R., Viallon, V., Morgan, S. L., Dobričić, V., Deecke, L., Schessner, J. P., Smith-Byrne, K., Birtles, D., Zhao, Y., et al. (2025) · Research Square · doi:10.1101/2025.08.20.25334061 · Cited by 6
Growth and differentiation factor 15: An emerging therapeutic target for brain diseases
Zhou, Y., Dou, L., Wang, L., Chen, J., Mao, R., Zhu, L., Liu, D., & Zheng, K. (2025) · BioScience Trends · doi:10.5582/bst.2024.01305 · Cited by 6
Self-citationPlasma GDF15 affects long-term dementia risk and alters neuroimmune signaling
Blew, C., Duggan, M. R., Tsitsipatis, D., Gómez, G., Rodriguez-Hernandez, Z., Pilling, L. C., Chen, J., Jacobsen, E. M., Dark, H. E., Lu, Y., et al. (2026) · Science Advances · doi:10.1126/sciadv.aec7614 · Cited by 11
Self-citationA Frailty‐Based Plasma Proteomic Signature Capturing Overall Health and Well‐Being in Older Adults
Sathyan, S., Liu, F., Tanaka, T., Ferrucci, L., Ayers, E. I., Windham, B. G., Gao, T., Weiss, E. F., Candia, J., Coresh, J., et al. (2025) · Aging Cell · doi:10.1111/acel.70144 · Cited by 6
“Loss of NDST1 N-sulfation activity is associated with impaired cognitive functions, defective craniofacial development, delayed ossification, and impaired mandibular and temporomandibular joint development (Khosrowabadi et al. 2024; Walker et al. 2023; Whitelock and Melrose 2011).”
Self-citationSchmid, A., Wilfurth, E., Höpfinger, A., Behrendt, M., Islami, E., Karrasch, T., Berghoff, M., & Schäffler, A. (2025) · Scientific Reports · doi:10.1038/s41598-025-14846-8 · Cited by 8
Drouin, S. M., Kuo, P., Blew, C., Duggan, M. R., Chen, D., Smith, H. M., Chen, J., Giorgio, K., Gómez, G., Moore, A. Z., et al. (2025) · Aging Cell · doi:10.1111/acel.70281 · Cited by 6
Self-citationDebette, S., Caro, I., Western, D., Namba, S., Sun, N., Kawaguchi, S., He, Y., Fujita, M., Roshchupkin, G., D'Aoust, T., et al. (2024) · doi:10.21203/rs.3.rs-4535534/v1 · Cited by 5
“The APOE hotspot included four proteins encoded by genes in genome-wide or gene-wide signi�cant risk loci for WMH 20 and extreme-cSVD 23 (APOE, MRPL38, SULT1B1, and MSRA; Supplementary Tables 6–9, Extended Data Fig.”
BackgroundSelf-citationSex-aware causal inference assessment of the immune system in complex neurodegenerative diseases
Lona‐Durazo, F., Ross, B., Pilon, M., Greicius, M. D., Dubé, M., Belloy, M. E., McLaughlin, R. L., & Taliun, S. A. G. (2025) · Brain · doi:10.1093/brain/awaf474 · Cited by 5
“…GWAS (i.e. ADGRE2, COLEC11); although, we note that observational studies associating protein levels with disease status have not highlighted them either, 68-73 which could be due to non-genetic factors influencing protein levels at the time measurements were taken in observational studies.”
OMG! A proteomic determinant of neurodegenerative resiliency
Duggan, M. R., Oh, H. S., Frank, P., Gómez, G., Zweibaum, D. A., Cui, Y., Chen, J., Surapaneni, A., Blew, C., Dark, H. E., et al. (2026) · Molecular Neurodegeneration · doi:10.1186/s13024-025-00921-1 · Cited by 5
“Because proteins in peripheral circulation can originate from the brain and interact with CNS cell types, biofluid proteomics (e.g., SomaScan™ assay) can reveal scalable, readily accessible predictors and drivers of dementia and other age-related neurological outcomes [4–6].”
Self-citationBoginskaya, I. A., Slipchenko, E. A., Safiullin, R. R., Afanas'ev, K. N., Sedova, M., Ryzhikov, I. A., & Merzlikin, A. M. (2024) · Sensors and Actuators A Physical · doi:10.1016/j.sna.2024.115700 · Cited by 5
An appraisal at a glance of metallome and disease biomarkers
López, R., Pereira, F. J., & Aller, A. J. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.117931 · Cited by 4
Plasma Proteomic Analysis for Alzheimer’s Disease Biomarkers, Pathways, and Subgroup Identification
Peña‐Bautista, C., Álvarez‐Sánchez, L., Balaguer, Á., Ferré‐González, L., Peretó, M., Baquero, M., & Cháfer‐Pericás, C. (2025) · Journal of Proteome Research · doi:10.1021/acs.jproteome.5c00513 · Cited by 5
Proteomics-based aging clocks in midlife or late-life and their associated risk of dementia
Sedaghat, S., Park, S., Walker, R. F., Wang, S., Liu, J., Hughes, T. M., Sabayan, B., Tang, W., Coresh, J., Pankow, J. S., et al. (2025) · Communications Medicine · doi:10.1038/s43856-025-01096-y · Cited by 10
Self-citationOrgan-specific aging in the plasma proteome predicts disease
Duggan, M. R., & Walker, K. A. (2024) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2024.01.005 · Cited by 4
Self-citationIs the Relationship Between Cardiovascular Disease and Alzheimer’s Disease Genetic? A Scoping Review
Moore, A. K., & Ritchie, M. D. (2024) · Genes · doi:10.3390/genes15121509 · Cited by 5
Alanko, V., Mravinacová, S., Hall, A., Hagman, G., Mohanty, R., Westman, E., Nilsson, P., Kivipelto, M., Månberg, A., & Matton, A. (2025) · Brain Communications · doi:10.1093/braincomms/fcaf078 · Cited by 3
“44,45 Another of the identified main contributors to PC 3 was the astrocytic AQP4, which is required for brain fluid homeostasis and was previously found to be elevated in CSF of Alzheimer’s patients.”
Liu, W.-Z., Huang, L., Chi, S., Ma, Y., Tan, C., Tan, L., Initiative, A. D. N., & Xu, W. (2025) · Translational Psychiatry · doi:10.1038/s41398-025-03526-w · Cited by 7
Abdolkarimi, D., Liu, Y., Gilchrist, L., Calhas, S., Waters, S., Marshall, C. R., & Proitsi, P. (2026) · Alzheimer s Research & Therapy · doi:10.1186/s13195-025-01951-z · Cited by 4
“…of dementia, there has been a focus on identifying protein biomarkers in middle-aged adults which can hint at dysregulated pathways before the presentation of disease manifestations and recent studies have been exploring proteomic signatures associated with the incidence of dementia [8–10].”
The Potential Use of Matrix Metalloproteinases in Alzheimer’s Disease Therapy
Krawczuk, D., & Mroczko, B. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15041555 · Cited by 4
Plasma proteomic characterization of motoric cognitive risk and mild cognitive impairment
Gómez, G., Sathyan, S., Chen, J., Fornage, M., Schlosser, P., Peng, Z., Cordon, J., Palta, P., Sullivan, K., Tin, A., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.14429 · Cited by 5
Self-citationPlasma proteins and herpes simplex virus infection: a proteome-wide Mendelian randomization study
Fu, C., Xu, W., Xu, X., Zhao, F., Zheng, C., & Yin, Z. (2025) · Virus Genes · doi:10.1007/s11262-025-02145-3 · Cited by 5
An, L., Binette, A. P., Hristovska, I., Vilkaite, G., Xiao, Y., Zendehdel, R., Dong, Z., Smets, B., Saloner, R., Tasaki, S., et al. (2025) · medRxiv · doi:10.1101/2025.06.27.25330344 · Cited by 3
“This study distinguishes itself from other neurodegenerative disease proteomics studies 75–78 due to the focus here on making individual-level predictions on new cases, and by training a model to recognize multiple co-pathologies rather than on differential diagnosis.”
Identifying Alzheimer’s disease-related pathways based on whole-genome sequencing data
Wang, Y., Taihang, L., He, Y., Tan, P., Tan, P., Huang, D., Huang, D., Wen, T., Shao, L., Wang, J., et al. (2025) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2025.09.013 · Cited by 2
“Furthermore, analyses of transcriptomic [8,9] and proteomic [10,11] differences between AD patients and controls have uncovered several new AD-related pathways.”
Gouilly, D., Da-Costa, A., Vrillon, A., Pistono, A., Goubeaud, M., Bertrand, E., Germain, J., Ainaoui, N., Bras, S., Catalá, H., et al. (2025) · Journal of Neuroinflammation · doi:10.1186/s12974-025-03625-x · Cited by 3
Xi, J., He, K., Hou, L., Smets, B., Miller, S., Saad, Z. S., Whelan, C. D., Ruiz, A., Puerta, R., Cano, A. C., et al. (2026) · npj Dementia · doi:10.1038/s44400-025-00053-9 · Cited by 5
Dai, S., Chen, Y., Huang, S., Long, G., Huang, H., & Xu, C. (2026) · Journal of Proteome Research · doi:10.1021/acs.jproteome.5c00555 · Cited by 2
Novel Plasma Proteomic Markers and Risk of Venous Thromboembolism
Tang, W., Li, A., Austin, T. R., Brækkan, S. K., Nøst, T. H., Li, X., Deo, R., Dubin, R. F., Ganz, P., Guan, W., et al. (2026) · Circulation · doi:10.1161/circulationaha.125.074493 · Cited by 3
“Similar patterns have been reported, for example for SERPINA3 74 and angio-statin 75 with dementia, and for IL6 and soluble IL6R with coronary heart disease (CHD).”
Self-citationThe emerging role of high-throughput proteomics in advancing precision medicine
You, J., Deng, Y., Chen, L., Wang, L., Guo, Y., Li, Z.-Y., Feng, J., Yu, Y., & Cheng, W. (2026) · 中国科学通报:英文版 · doi:10.1016/j.scib.2026.02.054 · Cited by 4
Proteomic signatures as biomarkers of atherosclerosis burden
Zhang, L., Omarov, M., Xu, L., Das, B., Luo, H., Hauck, S. M., Petrera, A., Yu, Z., Goonewardena, S. N., Zeggini, E., et al. (2026) · Cardiovascular Research · doi:10.1093/cvr/cvag140 · Cited by 3
Plasma proteins associated with the brain age gap
Johnson, E. C. B. (2025) · Nature Aging · doi:10.1038/s43587-024-00780-3 · Cited by 3
Elenbaas, J. S., Lee, P. C., Patel, V., & Stitziel, N. O. (2025) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-061724-080905 · Cited by 3
Isik, F. I., Thomson, S., Cueto, J. F., Spathos, J., Breit, S. N., Tsai, V. W.-W., Brown, D. A., & Finney, C. A. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.07.07.600156 · Cited by 2
Blood biomarkers of Alzheimer’s disease: findings from proteomics
Wang, Y., Niu, X., Zhen, W., Zhang, B., Chen, L., Liu, Y., Sun, W., & Peng, D. (2025) · Postgraduate Medical Journal · doi:10.1093/postmj/qgaf039 · Cited by 1
Park, S., Kim, D., Choi, J. H., Hong, C. H., Son, S. J., Roh, H. W., Shin, H., & Woo, H. G. (2025) · Briefings in Bioinformatics · doi:10.1093/bib/bbaf366 · Cited by 1
“Our findings also covered well-known dementia-associated proteins, such as BCAN, CNTN5, and NCAN [81, 82], along with identifying recently promising biomarkers, including IL18, MMP12, TNFSF12, and UNC5C [63, 83–85], where these biomarkers presented the highest protein importance in their clusters.”
Malarte, M., Chiotis, K., Ioannou, K., & Rodriguez‐Vieitez, E. (2025) · Journal of Neurochemistry · doi:10.1111/jnc.70222 · Cited by 3
“Inflammatory markers in preclinical AD (Engelhart et al. 2004; Walker et al. 2023) differentiate mild cognitive impairment (MCI) progressors and non-progressors to AD dementia (Kivisäkk et al. 2022).”
Huang, B., Tian, Y., & Li, J. (2025) · Hepatobiliary & pancreatic diseases international · doi:10.1016/j.hbpd.2025.11.005 · Cited by 1
Park, J. H., Choi, J., Kim, G.-Y., Kim, M., Park, S., & Koh, Y. H. (2025) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2025.11.021 · Cited by 4
Zhao, Y.-H., Ning, J., Zhang, X., Qu, R., Lv, C.-C., & Zhang, Y.-Z. (2026) · Medicine · doi:10.1097/md.0000000000045715 · Cited by 1
“[22] This study investigated the causal relationship between 4907 plasma proteins and AD via 2-sample MR, drug prediction, molecular docking, and single-cell sequencing.”
We wait for disease to shout—What if we listened when biology whispered?
Rappaport, N., Schweickart, A., Hood, L., & Price, N. D. (2026) · Cell Systems · doi:10.1016/j.cels.2025.101509 · Cited by 2
Plasma proteomic profiles linked to suicidal behaviors
Zhang, B., You, J., Rolls, E. T., Ren, P., Li, Y., Zhang, W., Sahakian, B. J., Li, F., Feng, J., & Cheng, W. (2026) · Nature Mental Health · doi:10.1038/s44220-025-00582-5 · Cited by 2
“In accordance with previous network-based proteomic analyses 47,48 , we set a minimum module size of 20 and employed a Spearman filter method with a soft power of β = 2, https://doi.org/10.1038/s44220-025-00582-5 the TRRUST database for transcriptional regulator enrichment and the STRING database…”
InfluentialDuggan, M. R., Jacobsen, E. P., Yang, S., Zeng, X., Kandala, S., Joynes, C. M., Karikari, T. K., Nimgaonkar, V. L., Kamboh, M. I., Snitz, B. E., et al. (2026) · Journal of Neuroinflammation · doi:10.1186/s12974-026-03800-8 · Cited by 1
“GWAS summary statistics of general cognitive performance ( n = 257,841) and Aβ PET ( n = 13,409) were used to assess the outcomes a cytotoxic antimicrobial peptide), which exhibited the strongest statistical association in meta-analyzed results (sTable 18–20; sFigure 14).”
Self-citationKrishnamachary, B., Lee, H., Wang, Z., Yang, W. W., Li, H., Lei, Z., Wu, J., & Li, Y. (2026) · GeroScience · doi:10.1007/s11357-026-02317-5 · Cited by 2
McNaugher, G. A., McColgan, L., Church, M., McClean, P. L., Gibson, D. S., Murray, E. K., Coyle, S., & McGilligan, V. (2026) · Journal of Alzheimer s Disease · doi:10.1177/13872877261456729 · Cited by 1
Metadata
- Authors
- Walker, K. A., Chen, J., Shi, L., Yang, Y., Fornage, M., Zhou, L., Schlosser, P., Surapaneni, A., Grams, M. E., Duggan, M. R., Peng, Z., Gomez, G. T., Tin, A., Hoogeveen, R. C., Sullivan, K. J., Ganz, P., Lindbohm, J. V., Kivimaki, M., Nevado-Holgado, A. J., Buckley, N., Gottesman, R. F., Mosley, T. H., Boerwinkle, E., Ballantyne, C. M., & Coresh, J.
- Affiliations
- National Institute on Aging (US)
- Johns Hopkins University (US)
- Novo Nordisk Research Centre Oxford (NNRCO), Oxford OX3 7FZ, UK.
- Brown Foundation Institute of Molecular Medicine for the Prevention of Human Diseases (US)
- Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD 21210, USA.
- University of Mississippi Medical Center (US)
- Baylor College of Medicine (US)
- University of California, San Francisco (US)
- Broad Institute (US)
- Department of Mental Health of Older People, Faculty of Brain Sciences, University College London, London WC1E 6BT, UK.
- Department of Psychiatry, University of Oxford, Oxford OX1 2JD, UK.
- University of Oxford (GB)
- National Institute of Neurological Disorders and Stroke (US)
- Corresponding author
- Walker, Keenan A.
- Coresh, Josef
- ORCID
- Walker, Keenan A.
- Shi, Liu
- Yang, Yunju
- Fornage, Myriam
- Schlosser, Pascal
- Surapaneni, Aditya
- Grams, Morgan E.
- Duggan, Michael R.
- Peng, Zhongsheng
- Gomez, Gabriela T.
- Tin, Adrienne
- Hoogeveen, Ron C.
- Sullivan, Kevin J.
- Ganz, Peter
- Lindbohm, Joni V.
- Kivimaki, Mika
- Nevado-Holgado, Alejo J.
- Buckley, Noel
- Gottesman, Rebecca F.
- Mosley, Thomas H.
- Boerwinkle, Eric
- Ballantyne, Christie M.
- Coresh, Josef
- Venue
- Science Translational Medicine
- Published
- 2023-07-19
- Volume
- 15
- Issue
- 705
- Pages
- eadf5681-eadf5681
- ISSN
- 1946-6234 (ISSN-L)
- 1946-6242
- PMC
- PMC10665113
- OpenAlex
- W4384819023
- Cited by
- 148
- References
- 103
- Citations by year
- 2026: 42 · 2025: 56 · 2024: 39 · 2023: 11
- FWCI
- 29.79
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science Translational Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Digital Commons-TMC (Texas Medical Center) (submittedVersion)
- UCL Discovery (University College London) (submittedVersion)
- FreiDok plus (Universitätsbibliothek Freiburg) (submittedVersion)
- Funders
- GlaxoSmithKline
- Wellcome Trust (221854/Z/20/Z, 350426)
- European Commission (H2020 SC1, H2020)
- Rosetrees Trust
- Deutsche Forschungsgemeinschaft (192904750, CRC992)
- Albert-Ludwigs-Universität Freiburg
- Päivikki ja Sakari Sohlbergin Säätiö
- National Institutes of Health (5u01hl096899-08, 5u01hl096902-08, S011676, Z99 AG999999, H2020)
- Gillings School of Public Health
- Horizon 2020 Framework Programme (H2020-SC1)
- Medical Research Council (S011676, MR/R024227/1, MR/S011676/1, MRC S011676)
- Medizinische Fakultät der Albert-Ludwigs-Universität Freiburg
- National Institute on Aging (U01AG058589, RF1AG062553, U01AG052409, R01AG056477, RF1AG059421, ZIAAG000349, ZIAAG000348, P30AG066546)
- National Heart, Lung, and Blood Institute (HHSN268201700004I, HHSN268201700001I, HHSN268201700005C, HHSN268201700003I, U01HL096814, U01-HL-096899, R01HL087641, R01HL059367, R01HL134320, HHSN268201700005I, U01-HL-096902, HHSN268201700001C, U01HL096917, HHSN268201700002I, HHSN268201700003C, HHSN268201700002C, R01HL070825, HHSN268201700004C, U01HL096812, K24HL155861, R01HL086694)
- National Institute of Diabetes and Digestive and Kidney Diseases (R01DK124399, R01DK100446, R01DK115534, R01DK108803)
- National Institute of Neurological Disorders and Stroke
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (R01AR073178)
- National Center for Research Resources (UL1RR025005)
- Janssen Pharmaceuticals
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- Alzheimer's disease, dementia risk, plasma proteins, biomarkers, proteomics, middle-aged adults, proteostasis, autophagy, neuroinflammation, cerebrospinal fluid biomarkers, GDF15, alpha-1-antichymotrypsin, coagulation, complement signaling, neurodegeneration, synaptic function, extracellular matrix, neuropsychological outcomes, dementia risk prediction
- MeSH terms
- Adult, Alzheimer Disease, Brain, Humans, Middle Aged, Biomarkers, Amyloid beta-Peptides, tau Proteins, Proteomics
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.